17.! Conconi!A,!Thieblemont!C,!Cascione!L,!Torri!V,!Kiesewetter!B,!Margiotta!Casaluci!G,!Gaidano!G,!
Raderer! M,! Cavalli! F,! Lopez! Guillermo! A( et( al:! Early( progression( of( disease( predicts( shorter(
survival(in(MALT(lymphoma(patients(receiving(systemic(treatment.!Haematologica(2020.!
18.! Thieblemont!C,!Cascione!L,!Conconi!A,!Kiesewetter!B,!Raderer!M,!Gaidano!G,!Martelli!M,!Laszlo!
D,! Coiffier! B,! Lopez! Guillermo! A( et( al:! A( MALT( lymphoma( prognostic( index.! Blood( 2017,!
130(12):1409>1417.!
19.! Heilgeist! A,! McClanahan! F,! Ho! AD,! Witzens>Harig! M:! Prognostic( value( of( the( Follicular(
Lymphoma( International( Prognostic( Index( score( in( marginal( zone( lymphoma:( an( analysis( of(
clinical(presentation(and(outcome(in(144(patients.!Cancer(2013,!119(1):99>106.!
20.! Arcaini! L,! Lazzarino! M,! Colombo! N,! Burcheri! S,! Boveri! E,! Paulli! M,! Morra! E,! Gambacorta! M,!
Cortelazzo! S,! Tucci! A( et( al:! Splenic( marginal( zone( lymphoma:( a( prognostic( model( for( clinical(
use.!Blood(2006,!107(12):4643>4649.!
21.! Noy! A,! de! Vos! S,! Thieblemont! C,! Martin! P,! Flowers! CR,! Morschhauser! F,! Collins! GP,! Ma! S,!
Coleman! M,! Peles! S( et( al:! Targeting( Bruton( tyrosine( kinase( with( ibrutinib( in(
relapsed/refractory(marginal(zone(lymphoma.!Blood(2017,!129(16):2224>2232.!
22.! Dreyling! M,! Morschhauser! F,! Bouabdallah! K,! Bron! D,! Cunningham! D,! Assouline! SE,! Verhoef! G,!
Linton!K,!Thieblemont!C,!Vitolo!U(et(al:!Phase(II(study(of(copanlisib,(a(PI3K(inhibitor,(in(relapsed(
or(refractory,(indolent(or(aggressive(lymphoma.!Ann(Oncol(2017,!28(9):2169>2178.!
23.! Kiesewetter!B,!Troch!M,!Dolak!W,!Mullauer!L,!Lukas!J,!Zielinski!CC,!Raderer!M:!A(phase(II(study(
of( lenalidomide( in( patients( with( extranodal( marginal( zone( B?cell( lymphoma( of( the( mucosa(
associated(lymphoid(tissue((MALT(lymphoma).!Haematologica(2013,!98(3):353>356.!
24.! Bertoni!F,!Rossi!D,!Raderer!M,!Zucca!E:!Marginal(Zone(Lymphomas.!Cancer(J(2020,!26(4):336>
347.!
25.! Grunenberg! A,! Kaiser! LM,! Woelfle! S,! Schmelzle! B,! Viardot! A,! Moller! P,! Barth! TF,! Muche! R,!
Dreyhaupt! J,! Buske! C:! Phase( II( trial( evaluating( the( efficacy( and( safety( of( the( anti?CD20(
monoclonal(antibody(obinutuzumab(in(patients(with(marginal(zone(lymphoma.!Future(Oncol(
2020,!16(13):817>825!
!
!
( (